1 1943 report of a pedigree with a sex-linked form of intellectual disability described what is now referred to as fragile X syndrome (FXS), caused by an expanded (.200) CGG trinucleotide repeat within the 59 untranslated region of the fragile X mental retardation 1 (FMR1) gene. This results in epigenetic silencing of the encoded fragile X mental retardation protein (FMRP).
Epigenetic diagnostics for neuropsychiatric disorders
Above the genome Martin and Bell's 1 1943 report of a pedigree with a sex-linked form of intellectual disability described what is now referred to as fragile X syndrome (FXS), caused by an expanded (.200) CGG trinucleotide repeat within the 59 untranslated region of the fragile X mental retardation 1 (FMR1) gene. This results in epigenetic silencing of the encoded fragile X mental retardation protein (FMRP). 1, 2 The term epigenetic refers to chemical modifications of DNA and associated chromatin proteins that alter activity states of the genome without requiring heritable changes to DNA itself. 3 Studies of inherited neuropsychiatric disorders have contributed greatly to our understanding of the molecular basis of human cognition, mood, and behavior; the field of neuroepigenetics continues to expand and gain importance. 4 FXS is now recognized as the most common inherited from of intellectual disability and the most frequent genetic cause of autism, affecting ;1/4,000 men and ;1/6,000 women. Continued investigation of genetic variation within the FMR1 locus at Xq27.3 and clinical phenotyping has led to the recognition of additional distinct (from FXS) clinical syndromes. Most notably, individuals with FMR1 premutation CGG trinucleotide expansions in the range of 55-199 exhibit reduced FMRP expression and elevated, potentially toxic FMR1 mRNA levels, leading to either fragile X-associated primary ovarian insufficiency or a late-onset neurodegenerative disorder called fragile X-associated tremor/ataxia syndrome. 2, 5 Given the prevalence of FMR1 premutations (;1/150 women and ;1/450 men) and variable penetrance, there exists a substantial need to develop effective prognostic markers and preventive treatments.
In this issue of Neurology ® , Cornish et al. 6 provide an important example of integrative genetic and epigenetic analysis to classify persons with FMR1 premutations, exhibiting a range of dysexecutive/social anxiety and depressive phenotypes. In their study, CGG repeat size, FMR1 mRNA levels, and level of DNA methylation in CpG dinucleotide sites in peripheral blood were analyzed in 35 female participants with premutations and 35 matched, healthy women.
While the Southern blot used to assess DNA methylation levels in FXS diagnostics relies on methylation-sensitive restriction sites within a 52-site CpG island located 59 proximal to the FMR1 transcriptional start site, and on CGG expansion, this assessment has shown limited prognostic value in premutation women. As an alternative, Cornish et al. 6 used a more precise and quantitative mass spectrometry-based assay to measure methylation of a set of 9 CpG sites spanning exon 1/intron 1 in a region 39 to the CGG repeat site-a genomic region known to form RNA:DNA hybrids that regulate FMRP expression. Upon doing so, Cornish et al. 6 found that FMR1 intron 1 CpG methylation levels, particularly sites CpG 10-12, enabled FMR1 premutation women to be grouped dichotomously based upon their likelihood of exhibiting dysexecutive or psychiatric symptoms. Here, the precision of mass spectrometry-based diagnostics to measure specific DNA modification sites out of the entirety of the human genome, rather than having to depend on differential separation of DNA fragments, was key. Ultimately, the discovery of such epigenotypephenotype correlations in clinically accessible blood samples with easily scalable, highly quantitative, and inexpensive methodology as used by Cornish et al. 6 is highly likely to assist in the early diagnosis, risk assessment, and patient population stratification for clinical trials in FMR1 premutation subjects.
However, while there are strengths to this integrated clinical phenotyping and genetic-epigenetic study of Cornish et al., 6 it is not without its shortcomings. These include the modest size of the cohort analyzed, the absence of replication of the findings in an additional cohort, and the lack of longitudinal assessment of participants. The extent to which assays of other epigenetic modifications might improve the classification is also unclear; this includes consideration of alternative DNA modifications, such as 5-hydroxymethylcytosine, as well as histone modifications. 7 Here, the use of nextgeneration sequencing technologies that allow for genome-wide assessment of DNA, as well as histone, modifications through chromatin immunoprecipitation would enable comprehensive assessment of the epigenome in persons with FMR1 premutation. 8 Finally, the molecular basis for the epigenetic differences between persons with FMR1 premutation observed by Cornish et al. 6 remains unknown. Here, the capacity to generate patient-specific, induced pluripotent stem cells (iPSCs) and their differentiation to specific neuronal subtypes ex vivo may allow more accurate measurement and modulation of the epigenetic state of the FMR1 locus. The feasibility of this approach is suggested by studies demonstrating that iPSC models from FXS subjects recapitulate the elevation of DNA methylation and loss of FMR1 expression in subjects with full mutation and that elevation of FMR1 expression levels occur in neurons with premutation sized repeats. 9, 10 The extent to which similar epigenotype-phenotype correlations will be observed for other neuropsychiatric disorders awaits further studies. In this context, the findings of McMillan et al., 11 also in this issue of Neurology, suggest a protective effect of DNA methylation in individuals carrying hexanucleotide repeat expansions in the C9orf72 gene, a common, autosomal dominant cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Beyond Mendelian disorders, the discovery of epigenotype-phenotype correlations may also be important for understanding the etiology of genetically complex neuropsychiatric disorders. It is increasingly recognized that common genetic risk variants reside within either nonprotein coding regions of genes or within intergenic regions. Understanding how this type of genetic variation plays a role in disease pathogenesis will require elucidation of epigenetic regulatory mechanisms that may be disrupted due to changes in promoters, enhancers, or noncoding RNAs. Thus, gaining a comprehensive understanding of neuroepigenetic regulatory logic may add a new molecular tool to the diagnostic armamentarium for a range of neuropsychiatric disorders.
Finally, through advances in the development of pharmaceutical agents that are allowing the targeting of an increasingly diverse set of epigenetic mechanisms, 12 as well as the growing ability to harness molecular tools for epigenome editing, 13 it may be feasible, in the not so distant future, to reverse, or prevent, epigenomic dysregulation, thereby providing the next generation of disease-modifying, epigeneticsbased neurotherapeutics that may leave a long-lasting mark on the field of neuropsychiatry.
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